<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMPICILLIN AND SULBACTAM- ampicillin sodium and sulbactam sodium injection, powder, for solution </strong><br>Sagent Pharmaceuticals<br></p></div>
<h1>AMPICILLIN AND SULBACTAM FOR INJECTION, USP<br>(For IV Use)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION</span></td></tr></tbody>
</table>
<p class="First">SAGENT™<br>Rx only
</p>
<p><span class="Bold">To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Ampicillin and Sulbactam for Injection, USP is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration.
</p>
<p>Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C<span class="Sub">16</span>H<span class="Sub">18</span>N<span class="Sub">3</span>NaO<span class="Sub">4</span>S. The structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Ampicillin Sodium Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35606b43-5914-423c-9bc7-fa3957eb2563&amp;name=amp04-0001-01.jpg">
</div>
<p>Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C<span class="Sub">8</span>H<span class="Sub">10</span>NNaO<span class="Sub">5</span>S with a molecular weight of 255.22. The structural formula is:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Sulbactam Sodium Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35606b43-5914-423c-9bc7-fa3957eb2563&amp;name=amp04-0001-02.jpg">
</div>
<p>Ampicillin and Sulbactam for Injection, USP, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. Ampicillin and Sulbactam for Injection, USP dry powder is freely soluble in aqueous diluents to yield <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8 and 10.
</p>
<p>Dilute solutions (up to 30 mg ampicillin and 15 mg sulbactam per mL) are essentially colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow. The pH of dilute solutions remains the same.
</p>
<p>Each sterile Pharmacy Bulk Package contains 15 g Ampicillin and Sulbactam for Injection, USP (equivalent to 10 g ampicillin as the sodium salt plus 5 g sulbactam as the sodium salt). The sodium content is approximately 1150 mg (50 mEq) sodium.
</p>
<p>Ampicillin and Sulbactam for Injection, USP Pharmacy Bulk Package is a bottle containing a sterile preparation of ampicillin sodium and sulbactam sodium for parenteral use that contains many single doses. The Pharmacy Bulk Package is for use in a pharmacy admixture setting; it provides many single doses of Ampicillin and Sulbactam for Injection, USP for addition to suitable parenteral fluids in the preparation of admixtures for intravenous infusion. (See <a href="#s42">DIRECTIONS FOR USE - Directions for Proper Use of Pharmacy Bulk Package.</a>) <span class="Bold">FURTHER DILUTION IS REQUIRED BEFORE USE.</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam for injection, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of ampicillin alone. Peak ampicillin serum levels ranging from 109 to 150 mcg/mL are attained after administration of 2000 mg of ampicillin plus 1000 mg sulbactam and 40 to 71 mcg/mL after administration of 1000 mg ampicillin plus 500 mg sulbactam. The corresponding mean peak serum levels for sulbactam range from 48 to 88 mcg/mL and 21 to 40 mcg/mL, respectively. After an intramuscular injection of 1000 mg ampicillin plus 500 mg sulbactam, peak ampicillin serum levels ranging from 8 to 37 mcg/mL and peak sulbactam serum levels ranging from 6 to 24 mcg/mL are attained.
</p>
<p>The mean serum half-life of both drugs is approximately 1 hour in healthy volunteers.
</p>
<p>Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of ampicillin and sulbactam for injection to individuals with normal renal function. Somewhat higher and more prolonged serum levels of ampicillin and sulbactam can be achieved with the concurrent administration of probenecid.
</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of ampicillin and sulbactam for injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin (see <span class="Bold"><a href="#s38">DOSAGE AND ADMINISTRATION</a></span> section).
</p>
<p>Ampicillin has been found to be approximately 28% reversibly bound to human serum protein and sulbactam approximately 38% reversibly bound.
</p>
<p>The following average levels of ampicillin and sulbactam were measured in the tissues and fluids listed:
</p>
<a name="t1"></a><table width="100%">
<caption><span>TABLE 1  Concentration of Ampicillin and Sulbactam for Injection in Various Body Tissues and Fluids
</span></caption>
<col align="left" width="31.967%">
<col align="left" width="30.100%">
<col align="left" width="37.933%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Fluid or Tissue</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Dose</span><br><span class="Bold">(grams)</span><br><span class="Bold">Ampicillin/Sulbactam</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Concentration</span><br><span class="Bold">(mcg/mL or mcg/g)</span><br><span class="Bold">Ampicillin/Sulbactam</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Peritoneal Fluid
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5/0.5 IV
</td>
<td class="Botrule Rrule" align="center" valign="middle">7/14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Fluid (Cantharides)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5/0.5 IV
</td>
<td class="Botrule Rrule" align="center" valign="middle">8/20
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Tissue Fluid
</td>
<td class="Botrule Rrule" align="center" valign="middle">1/0.5 IV
</td>
<td class="Botrule Rrule" align="center" valign="middle">8/4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Intestinal Mucosa
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5/0.5 IV
</td>
<td class="Botrule Rrule" align="center" valign="middle">11/18
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Appendix
</td>
<td class="Botrule Rrule" align="center" valign="middle">2/1 IV
</td>
<td class="Botrule Rrule" align="center" valign="middle">3/40
</td>
</tr>
</tbody>
</table>
<p>Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration of ampicillin and sulbactam for injection.
</p>
<p>The pharmacokinetics of ampicillin and sulbactam in pediatric patients receiving ampicillin and sulbactam for injection are similar to those observed in adults. Immediately after a 15-minute infusion of 50 to 75 mg ampicillin and sulbactam for injection/kg body weight, peak serum and plasma concentrations of 82 to 446 mcg ampicillin/mL and 44 to 203 mcg sulbactam/mL were obtained. Mean half-life values were approximately 1 hour.
</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>MICROBIOLOGY
</h1>
<p class="First">Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. (Ampicillin is, however, degraded by beta-lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes.)
</p>
<p>A wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam. Although sulbactam alone possesses little useful antibacterial activity except against the <span class="Italics">Neisseriaceae,</span> whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.
</p>
<p>The presence of sulbactam in the ampicillin and sulbactam for injection formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials. Thus, ampicillin and sulbactam for injection possesses the properties of a broad-spectrum antibacterial and a beta-lactamase inhibitor.
</p>
<p>While <span class="Italics">in vitro</span> studies have demonstrated the susceptibility of most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms, clinical efficacy for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than those included in the <span class="Bold"><a href="#s9">INDICATIONS AND USAGE</a></span> section has not been documented.
</p>
<p><span class="Bold">Gram-Positive Bacteria:
</span><span class="Italics">Staphylococcus aureus</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Staphylococcus epidermidis</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Staphylococcus saprophyticus</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Streptococcus faecalis</span><span class="Sup">†</span> (Enterococcus), <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">†</span> (formerly <span class="Italics">D. pneumoniae</span>), <span class="Italics">Streptococcus pyogenes</span><span class="Sup">†</span>, <span class="Italics">Streptococcus viridans</span><span class="Sup">†</span>.
</p>
<p><span class="Bold">Gram-Negative Bacteria:
</span><span class="Italics">Hemophilus influenzae</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Moraxella (Branhamella) catarrhalis</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Escherichia coli</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Klebsiella</span> species (all known <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are beta-lactamase producing), <span class="Italics">Proteus mirabilis</span> (beta-lactamase and non-beta-lactamase producing), <span class="Italics">Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Morganella morganii,</span> and <span class="Italics">Neisseria gonorrhoeae</span> (beta-lactamase and non-beta-lactamase producing).
</p>
<p><span class="Bold">Anaerobes:
</span><span class="Italics">Clostridium</span> species<span class="Sup">†</span>, <span class="Italics">Peptococcus</span> species<span class="Sup">†</span>, <span class="Italics">Peptostreptococcus</span> species, <span class="Italics">Bacteroides</span> species, including <span class="Italics">B. fragilis</span>.
</p>
<p><span class="Sup">†</span> These are not beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and, therefore, are susceptible to ampicillin alone.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.1"></a><p></p>
<h2>Susceptibility Testing
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.1.1"></a><p></p>
<p class="First"><span class="Bold">Diffusion Technique:</span> For the disk diffusion method of susceptibility testing, a 20 mcg (10 mcg ampicillin + 10 mcg sulbactam) disk should be used. The standardized procedure<span class="Sup">1,2</span> requires the use of a standardized inoculum concentration. With this procedure, a report from the laboratory of "Susceptible" indicates that the infecting organism is likely to respond to ampicillin and sulbactam for injection therapy and a report of "Resistant" indicates that the infecting organism is not likely to respond to therapy. An "Intermediate" susceptibility report suggests that the infecting organism would be susceptible to ampicillin and sulbactam for injection if a higher dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues or fluids (e.g., urine) in which high antibacterial levels are attained.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-4.1.2"></a><p></p>
<p class="First"><span class="Bold">Dilution Techniques:</span> Broth, agar, microdilution or equivalent methods may be used to determine the minimal inhibitory concentration (MIC) value for susceptibility of bacterial isolates using standardized methods, inoculums and concentrations of ampicillin/sulbactam.<span class="Sup">2,3,4</span></p>
<p>The recommended dilution method employs a constant ampicillin/sulbactam ratio of 2:1 in all tubes with increasing concentrations of ampicillin. MIC's are reported in terms of ampicillin concentration in the presence of sulbactam at a constant 2 parts ampicillin to 1 part sulbactam.
</p>
<a name="t2"></a><table width="100%">
<caption><span>TABLE 2 Recommended Ampicillin/Sulbactam, Disk Diffusion and MIC Susceptibility Ranges<span class="Sup">a, b, c</span> (Zone diameter in mm)
</span></caption>
<col align="left" width="22.429%">
<col align="left" width="11.514%">
<col align="left" width="14.543%">
<col align="left" width="12.114%">
<col align="left" width="11.514%">
<col align="left" width="14.543%">
<col align="left" width="13.343%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">a</span> The non-beta-lactamase producing organisms which are normally susceptible to ampicillin, such as <span class="Italics">Streptococci,</span> will have similar zone sizes as for ampicillin disks.
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">b
</span><span class="Italics">Staphylococci</span> resistant to methicillin, oxacillin, or nafcillin must be considered resistant to ampicillin and sulbactam for injection.
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">c</span> The quality control cultures should have the following assigned daily ranges for ampicillin/sulbactam (see <span class="Bold"><a href="#t3">TABLE 3</a></span>):
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Organisms
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle">Inhibition zone diameter (mm)
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle">MIC (mcg/mL of ampicillin)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">Resistant
</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate
</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible
</td>
<td class="Botrule Rrule" align="center" valign="middle">Resistant
</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate
</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Enterobacteriaceae, Acinetobacter calcoaceticus,</span><br><br><span class="Italics">Staphylococcus spp.</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 11
</td>
<td class="Botrule Rrule" align="center" valign="middle">12 to 14
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 15
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 32
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 8
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 19
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 20
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 4
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 2
</td>
</tr>
</tbody>
</table>
<a name="t3"></a><table width="100%">
<caption><span>TABLE 3 Quality control ranges for ampicillin/sulbactam disk diffusion and MIC determinations
</span></caption>
<col align="left" width="21.080%">
<col align="left" width="18.580%">
<col align="left" width="30.908%">
<col align="left" width="29.432%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" colspan="2" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom">
<span class="Bold">Disk Diffusion</span><br><span class="Bold">(Zone diameter in mm)</span>
</td>
<td class="Botrule" align="center" valign="bottom">
<span class="Bold">MIC</span><br><span class="Bold">(mcg/mL ampicillin/</span><br><span class="Bold">mcg/mL sulbactam)</span>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="Italics">E. coli</span></td>
<td align="left" valign="middle">(ATCC 25922)
</td>
<td align="center" valign="middle">19 to 24
</td>
<td align="center" valign="middle">2/1-8/4
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="Italics">S. aureus</span></td>
<td align="left" valign="middle">(ATCC 25923)
</td>
<td align="center" valign="middle">29 to 37
</td>
<td align="center" valign="middle">Not applicable
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="Italics">E. coli</span></td>
<td align="left" valign="middle">(ATCC 35218)
</td>
<td align="center" valign="middle">13 to 19
</td>
<td align="center" valign="middle">8/4-32/16
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle"><span class="Italics">H. <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span></span></td>
<td class="Botrule" align="left" valign="middle">(ATCC 49247)
</td>
<td class="Botrule" align="center" valign="middle">14 to 22
</td>
<td class="Botrule" align="center" valign="middle">2/1-8/4
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.1"></a><p></p>
<p class="First"><span class="Bold">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> caused by beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus, Escherichia coli</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">, Klebsiella</span> spp.<span class="Sup">*</span> (including <span class="Italics">K. pneumoniae</span><span class="Sup">*</span>), <span class="Italics">Proteus mirabilis</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">, Bacteroides fragilis</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">, Enterobacter</span> spp.<span class="Sup">*</span>, and <span class="Italics">Acinetobacter calcoaceticus</span><span class="Italics"><span class="Sup">*</span></span>.
</p>
<p>NOTE: For information on use in pediatric patients see PRECAUTIONS-Pediatric Use and CLINICAL STUDIES sections.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.2"></a><p></p>
<p class="First"><span class="Bold">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></span> caused by beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli, Klebsiella</span> spp. (including <span class="Italics">K. pneumoniae</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">), Bacteroides</span> spp. (including <span class="Italics">B. fragilis</span>), and <span class="Italics">Enterobacter</span> spp.<span class="Sup">*</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.3"></a><p></p>
<p class="First"><span class="Bold">Gynecological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> caused by beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">,</span> and <span class="Italics">Bacteroides</span> spp.<span class="Sup">*</span> (including <span class="Italics">B. fragilis</span><span class="Italics"><span class="Sup">*</span></span><span class="Italics">).</span></p>
<p>*Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<p>While Ampicillin and Sulbactam for Injection, USP is indicated only for the conditions listed above, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection, USP due to its ampicillin content. Therefore, mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection, USP should not require the addition of another antibacterial.
</p>
<p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to Ampicillin and Sulbactam for Injection, USP.
</p>
<p>Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.
</p>
<p>To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam for Injection, USP and other antibacterial drugs, Ampicillin and Sulbactam for Injection, USP should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s13"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">The use of ampicillin and sulbactam for injection is contraindicated in individuals with a history of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).
</p>
<p>Ampicillin and sulbactam for injection is contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with ampicillin and sulbactam for injection.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s14"></a><a name="section-7"></a><p></p>
<h1>WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more apt to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to multiple allergens. There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe reactions when treated with cephalosporins. Before therapy with a penicillin, careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, and other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, ampicillin and sulbactam for injection should be discontinued and the appropriate therapy instituted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-7.2"></a><p></p>
<h2>Hepatotoxicity
</h2>
<p class="First">Hepatic dysfunction, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> has been associated with the use of ampicillin and sulbactam for injection. Hepatic toxicity is usually reversible; however, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported. Hepatic function should be monitored at regular intervals in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-7.3"></a><p></p>
<h2>
<span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ampicillin and sulbactam for injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial <span class="Underline">drug</span> use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s18"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s19"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> A high percentage of patients with mononucleosis who receive ampicillin develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus, ampicillin class antibacterials should not be administered to patients with mononucleosis. In patients treated with ampicillin and sulbactam for injection the possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with mycotic or bacterial pathogens should be kept in mind during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur (usually involving <span class="Italics">Pseudomonas</span> or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>), the drug should be discontinued and/or appropriate therapy instituted.
</p>
<p>Prescribing ampicillin and sulbactam for injection in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s20"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients should be counseled that antibacterial drugs including ampicillin and sulbactam for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ampicillin and sulbactam for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ampicillin and sulbactam for injection or other antibacterial drugs in the future.
</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s21"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with ampicillin and sulbactam for injection may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients. There are no data with ampicillin and sulbactam for injection and allopurinol administered concurrently. Ampicillin and sulbactam for injection and aminoglycosides should not be reconstituted together due to the <span class="Italics">in vitro</span> inactivation of aminoglycosides by the ampicillin component of ampicillin and sulbactam for injection.
</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s22"></a><a name="section-8.4"></a><p></p>
<p class="First"><span class="Bold">Drug/Laboratory Test Interactions:</span> Administration of ampicillin and sulbactam for injection will result in high urine concentration of ampicillin. High urine concentrations of ampicillin may result in false positive reactions when testing for the presence of glucose in urine using Clinitest™, Benedict's Solution or Fehling's Solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix™ or Testape™) be used. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with ampicillin and sulbactam for injection.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s23"></a><a name="section-8.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s24"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.6.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B:</span> Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ampicillin and sulbactam for injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. (See <span class="Bold"><a href="#s22">PRECAUTIONS-Drug/Laboratory Test Interactions</a></span> section.)
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s26"></a><a name="section-8.7"></a><p></p>
<p class="First"><span class="Bold">Labor and Delivery:</span> Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of ampicillin and sulbactam for injection in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s27"></a><a name="section-8.8"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when ampicillin and sulbactam for injection is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s28"></a><a name="section-8.9"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> The safety and effectiveness of ampicillin and sulbactam for injection have been established for pediatric patients one year of age and older for skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as approved in adults. Use of ampicillin and sulbactam for injection in pediatric patients is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance. (See <span class="Bold"><a href="#s3">CLINICAL PHARMACOLOGY</a>, <a href="#s9">INDICATIONS AND USAGE</a>, <a href="#s29">ADVERSE REACTIONS</a>, <a href="#s38">DOSAGE AND ADMINISTRATION</a></span>, and <span class="Bold"><a href="#s36">CLINICAL STUDIES</a></span> sections.)
</p>
<p>The safety and effectiveness of ampicillin and sulbactam for injection have not been established for pediatric patients for intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s29"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Adult Patients:</span> Ampicillin and sulbactam for injection is generally well tolerated. The following adverse reactions have been reported in clinical trials.
</p>
<p><span class="Bold">Local Adverse Reactions</span></p>
<dl>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at IV injection site - 3%
</dd>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> - 3%
</dd>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> – 1.2%
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-9.2"></a><p></p>
<h2>Systemic Adverse Reactions
</h2>
<p class="First">The most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in 3% of the patients and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in less than 2% of the patients.
</p>
<p>Additional systemic reactions reported in less than 1% of the patients were: <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, urine retention, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, tightness in throat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal pain</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> and mucosal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-9.2.1"></a><p></p>
<p class="First"><span class="Bold">Pediatric Patients:</span> Available safety data for pediatric patients treated with ampicillin and sulbactam for injection demonstrate a similar adverse events profile to those observed in adult patients. Additionally, atypical <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> has been observed in one pediatric patient receiving ampicillin and sulbactam for injection.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-9.3"></a><p></p>
<h2>Adverse Laboratory Changes
</h2>
<p class="First">Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:
</p>
<p><span class="Italics">Hepatic:</span> Increased AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), alkaline phosphatase, and LDH.
</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased hemoglobin</span>, hematocrit, RBC, WBC, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, platelets and increased <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, monocytes, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, eosinophils, and platelets.
</p>
<p><span class="Italics">Blood Chemistry:</span> Decreased serum albumin and total proteins.
</p>
<p><span class="Italics">Renal:</span> Increased BUN and creatinine.
</p>
<p><span class="Italics">Urinalysis:</span> Presence of RBC's and hyaline casts in urine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-9.4"></a><p></p>
<h2>Postmarketing Experience
</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following have been identified during post-marketing use ampicillin and sulbactam or other products containing ampicillin. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency, or potential causal connection to ampicillin and sulbactam for injection.
</p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena. Some individuals have developed positive direct Coombs Tests during treatment with ampicillin and sulbactam for injection, as with other beta-lactam antibacterials.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, abnormal hepatic function, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, black “hairy? tongue and <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (see <span class="Bold"><a href="#s13">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s14">WARNINGS</a></span> sections).
</p>
<p><span class="Bold">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> Serious and fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions (see <span class="Bold"><a href="#s14">WARNINGS</a></span> section).
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>.
</p>
<p><span class="Bold">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4177206" conceptname="Tubulointerstitial nephritis">Tubulointerstitial nephritis</span>.
</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalised exanthematous pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (see <span class="Bold"><a href="#s13">CONTRAINDICATIONS</a></span> section).
</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s35"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Neurological adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, may occur with the attainment of high CSF levels of beta-lactams. Ampicillin may be removed from circulation by hemodialysis. The molecular weight, degree of protein binding and pharmacokinetics profile of sulbactam suggest that this compound may also be removed by hemodialysis.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s36"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Pediatric Patients:</span> Data from a controlled clinical trial conducted in pediatric patients provided evidence supporting the safety and efficacy of ampicillin and sulbactam for injection for the treatment of skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Of 99 pediatric patients evaluable for clinical efficacy, 60 patients received a regimen containing intravenous ampicillin and sulbactam for injection, and 39 patients received a regimen containing intravenous cefuroxime. This trial demonstrated similar outcomes (assessed at an appropriate interval after discontinuation of all antimicrobial therapy) for ampicillin and sulbactam for injection – and cefuroxime - treated patients:
</p>
<a name="t4"></a><table width="100%">
<caption><span>TABLE 4
</span></caption>
<col align="left" width="50.383%">
<col align="left" width="25.991%">
<col align="left" width="23.625%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold Underline">Therapeutic Regimen</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold Underline">Clinical Success</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold Underline">Clinical Failure</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ampicillin and sulbactam for injection
</td>
<td class="Botrule Rrule" align="left" valign="middle">51/60 (85%)
</td>
<td class="Botrule Rrule" align="left" valign="middle">9/60 (15%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Cefuroxime
</td>
<td class="Botrule Rrule" align="left" valign="middle">34/39 (87%)
</td>
<td class="Botrule Rrule" align="left" valign="middle">5/39 (13%)
</td>
</tr>
</tbody>
</table>
<p>Most patients received a course of oral antimicrobials following initial treatment with intravenous administration of parenteral antimicrobials. The study protocol required that the following three criteria be met prior to transition from intravenous to oral antimicrobial therapy: 1) receipt of a minimum of 72 hours of intravenous therapy; 2) no documented <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> for prior 24 hours; and 3) improvement or resolution of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
<p>The choice of oral antimicrobial agent used in this trial was determined by susceptibility testing of the original pathogen, if isolated, to oral agents available. The course of oral antimicrobial therapy should not routinely exceed 14 days.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s38"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Ampicillin and sulbactam for injection may be used for parenteral administration. <span class="Bold">THE INTENT OF THIS PHARMACY BULK PACKAGE IS FOR PREPARATION OF SOLUTIONS FOR IV INFUSION ONLY.</span></p>
<p>Ampicillin and sulbactam for injection should be administered by slow intravenous injection over at least 10-15 minutes or can also be delivered in greater dilutions with 50-100 mL of a compatible diluent as an intravenous infusion over 15-30 minutes.
</p>
<p>The recommended adult dosage of ampicillin and sulbactam for injection is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to a range of 1 g ampicillin/0.5 g sulbactam to 2 g ampicillin/1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Pediatric Patients 1 Year of Age or Older:</span> The recommended daily dose of ampicillin and sulbactam for injection in pediatric patients is 300 mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours. This 300 mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to 200 mg ampicillin/100 mg sulbactam per kg per day. The safety and efficacy of ampicillin and sulbactam for injection administered via intramuscular injection in pediatric patients have not been established. Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4 grams per day. The course of intravenous therapy should not routinely exceed 14 days. In clinical trials, most children received a course of oral antimicrobials following initial treatment with intravenous ampicillin and sulbactam for injection. (See <span class="Bold"><a href="#s36">CLINICAL STUDIES</a></span> section.)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-12.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</h2>
<p class="First">In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of ampicillin and sulbactam for injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations:
</p>
<a name="t5"></a><table width="100%">
<caption><span>TABLE 5 Ampicillin And Sulbactam For Injection Dosage Guide for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></caption>
<col align="left" width="25.558%">
<col align="left" width="23.625%">
<col align="left" width="50.816%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Creatinine Clearance (mL/min/1.73m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Ampicillin/Sulbactam Half-Life (Hours)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Recommended</span><br><span class="Bold">Ampicillin And Sulbactam For Injection Dosage</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">≥ 30
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.5 to 3 g q 6 h to q 8 h
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">15 to 29
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.5 to 3 g q 12 h
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">5 to 14
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.5 to 3 g q 24 h
</td>
</tr>
</tbody>
</table>
<p>When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.
</p>
<table width="100%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="middle"></td>
<td align="left" valign="middle">Males
</td>
<td align="center" valign="middle">
<span class="Underline">weight (kg) × (140 - age)</span><br>72 × serum creatinine
</td>
<td align="left" valign="middle"></td>
</tr>
<tr class="Last">
<td align="left" valign="middle"></td>
<td align="left" valign="middle">Females
</td>
<td align="center" valign="middle">0.85 × above value
</td>
<td align="left" valign="middle"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-13"></a><p></p>
<h1>COMPATIBILITY, RECONSTITUTION AND STABILITY
</h1>
<p class="First">When concomitant therapy with aminoglycosides is indicated, ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the <span class="Italics">in vitro</span> inactivation of aminoglycosides by any of the aminopenicillins.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-14"></a><p></p>
<h1>DIRECTIONS FOR USE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-14.1"></a><p></p>
<h2>Intravenous Administration
</h2>
<p class="First"><span class="Bold">Directions for Proper Use of Pharmacy Bulk Package</span></p>
<p>Ampicillin and sulbactam for injection sterile powder for intravenous use may be reconstituted with any of the compatible diluents described in this insert. Solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization.
</p>
<p>After reconstitution of the Pharmacy Bulk Package, an appropriate volume should then be immediately diluted with a suitable parenteral diluent to yield solutions containing a concentration between 3 and 45 mg ampicillin and sulbactam for injection (2 to 30 mg ampicillin/1 to 15 mg sulbactam/mL).
</p>
<p>The 15 gram bottle may be reconstituted with either 92 mL Sterile Water for Injection or 0.9% Sodium Chloride Injection. The diluent should be added in two separate aliquots in a suitable work area, such as a laminar flow hood. Add 50 mL of solution, shake to dissolve. Then add an additional 42 mL and shake. The solution should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization. The resultant solution will have a final concentration of approximately 100 mg/mL ampicillin and 50 mg/mL sulbactam. The closure may be penetrated only one time after reconstitution, if needed, using a suitable sterile transfer device or dispensing set that allows for measured dispensing of the contents.
</p>
<p>After reconstitution, use within two hours if stored at room temperature, or within four hours if stored under refrigeration.
</p>
<p><span class="Bold">Reconstituted Bulk Solution Should Not Be Used For Direct Infusion</span></p>
<p>If the reconstituted bulk solution is stored for less than one hour at room temperature (20° to 25°C / 68° to 77°F) prior to further dilution, the use periods indicated in <a href="#t6">Table 6</a> apply for the diluted solutions.
</p>
<p>If the bulk solution is stored for one to two hours at room temperature (20° to 25°C / 68° to 77°F) and then diluted with Sterile Water for Injection or 0.9% Sodium Chloride Injection to the following concentrations, the use periods indicated in <a href="#t7">Table 7</a> apply.
</p>
<p>Any unused portions of solution that remain after the indicated time periods should be discarded.
</p>
<a name="t6"></a><table width="100%">
<caption><span>TABLE 6
</span></caption>
<col align="left" width="38.580%">
<col align="left" width="42.781%">
<col align="left" width="18.640%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Diluent</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Maximum Concentration (mg/mL)</span><br><span class="Bold">Ampicillin And Sulbactam For Injection (Ampicillin/Sulbactam)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Use Periods</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Sterile Water for Injection
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15) <br>30 (20/10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">8 hrs at 25±2°C <br>48 hrs at 5±3°C <br>72 hrs at 5±3°C
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">0.9% Sodium Chloride Injection
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15) <br>30 (20/10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">8 hrs at 25±2°C <br>48 hrs at 5±3°C <br>72 hrs at 5±3°C
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">5% Dextrose Injection
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 (20/10) <br>30 (20/10) <br>3 (2/1)
</td>
<td class="Botrule Rrule" align="center" valign="middle">2 hrs at 25±2°C <br>4 hrs at 5±3°C <br>2 hrs at 25±2°C
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Lactated Ringer's Injection
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15)
</td>
<td class="Botrule Rrule" align="center" valign="middle">8 hrs at 25±2°C <br>24 hrs at 5±3°C
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">M/6 Sodium Lactate Injection
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15)
</td>
<td class="Botrule Rrule" align="center" valign="middle">8 hrs at 25±2°C <br>12 hrs at 5±3°C
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">5% Dextrose in 0.45% Saline
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (2/1) <br>15 (10/5)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 hrs at 25±2°C <br>4 hrs at 5±3°C
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">10% Invert Sugar
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (2/1) <br>30 (20/10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 hrs at 25±2°C <br>3 hrs at 5±3°C
</td>
</tr>
</tbody>
</table>
<a name="t7"></a><table width="100%">
<caption><span>TABLE 7
</span></caption>
<col align="left" width="38.433%">
<col align="left" width="43.400%">
<col align="left" width="18.167%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">IV Solution</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Maximum Concentration (mg/mL)</span><br><span class="Bold">Ampicillin And Sulbactam For Injection (Ampicillin/Sulbactam)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Use Periods</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Sterile Water for Injection, USP
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 hrs at 25±2°C <br>24 hrs at 5±3°C
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">0.9% Sodium Chloride Injection, USP
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (30/15) <br>45 (30/15)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 hrs at 25±2°C <br>24 hrs at 5±3°C
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-14.1.1"></a><p></p>
<p class="First"><span class="Bold">Animal Pharmacology:</span> While reversible glycogenosis was observed in laboratory animals, this phenomenon was dose- and time-dependent and is not expected to develop at the therapeutic doses and corresponding plasma levels attained during the relatively short periods of combined ampicillin/sulbactam therapy in man.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s45"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Ampicillin and Sulbactam for Injection, USP (Pharmacy Bulk Package) is supplied as follows:
</p>
<table width="100%">
<col align="left" width="20.333%">
<col align="left" width="46.333%">
<col align="left" width="33.334%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top"><span class="Bold">Ampicillin and Sulbactam for Injection, USP</span></td>
<td align="left" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="left" valign="top">25021-144-99
</td>
<td align="left" valign="top">15 g equivalent of Ampicillin and Sulbactam for
</td>
<td align="left" valign="top">1 bottle per carton
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Injection, USP (10 g ampicillin as the sodium salt
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">plus 5 g sulbactam as the sodium salt) in a
</td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">Pharmacy Bulk Bottle
</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Ampicillin and Sulbactam for Injection, USP is a sterile off-white dry powder.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s46"></a><a name="section-15.1"></a><p></p>
<h2>Storage Conditions
</h2>
<p class="First">Prior to reconstitution, store dry powder at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-16"></a><p></p>
<h1>OTHER SIZE PACKAGES AVAILABLE
</h1>
<p class="First">Ampicillin and Sulbactam for Injection, USP is also available in single-dose vials supplied as follows:
</p>
<table width="100%">
<col align="left" width="20.333%">
<col align="left" width="46.333%">
<col align="left" width="33.334%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top"><span class="Bold">Ampicillin and Sulbactam for Injection, USP</span></td>
<td align="left" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="left" valign="top">25021-142-20
</td>
<td align="left" valign="top">1.5 g equivalent of Ampicillin and Sulbactam for
</td>
<td align="left" valign="top">10 vials per carton
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Injection, USP (1 g ampicillin as the sodium salt
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">plus 0.5 g sulbactam as the sodium salt) in a
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Single-Dose Vial
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">25021-143-30
</td>
<td align="left" valign="top">3 g equivalent of Ampicillin and Sulbactam for
</td>
<td align="left" valign="top">10 vials per carton
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Injection, USP (2 g ampicillin as the sodium salt
</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">plus 1 g sulbactam as the sodium salt) in a
</td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">Single-Dose Vial
</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s48"></a><a name="section-17"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard – Eleventh Edition</span>. CLSI document M02-A11. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement.</span> CLSI document M100- S24., Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard</span> – <span class="Italics">Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Eighth Edition</span>. CLSI document M11-A8, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
</ol>
<p class="First">Brands listed are the trademarks of their respective owners.
</p>
<p>SAGENT™<br>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in Italy<br>©2015 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: May 2015
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s49"></a><a name="section-18"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Bottle Label
</p>
<p>NDC 25021-144-99 Rx only
</p>
<p>Ampicillin and Sulbactam for Injection, USP
</p>
<p>15 grams per Pharmacy Bulk Package
</p>
<p>Equivalent to 10 g ampicillin plus 5 g sulbactam
</p>
<p>PHARMACY BULK PACKAGE
</p>
<p>NOT FOR DIRECT INFUSION
</p>
<p>THIS PHARMACY BULK PACKAGE IS NOT
</p>
<p>INTENDED TO BE DISPENSED AS A UNIT.
</p>
<p>Sterile
</p>
<p>For Intravenous Use
</p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35606b43-5914-423c-9bc7-fa3957eb2563&amp;name=amp04-0004-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMPICILLIN AND SULBACTAM 		
					</strong><br><span class="contentTableReg">ampicillin and sulbactam injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-144</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ampicillin sodium</strong> (ampicillin) </td>
<td class="formItem">ampicillin</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>sulbactam sodium</strong> (sulbactam) </td>
<td class="formItem">sulbactam</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-144-99</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065403</td>
<td class="formItem">08/12/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>069be4f7-860e-40c5-8356-275418eba609</div>
<div>Set id: 35606b43-5914-423c-9bc7-fa3957eb2563</div>
<div>Version: 6</div>
<div>Effective Time: 20150814</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
